---

Co-founder, President, and Chief Executive Officer at Scribe Therapeutics

Oakes has contributed to over 25 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. He received a PhD in Molecular and Cellular Biology from the University of California, Berkeley, in 2017, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics. Scribe Therapeutics was spun out of the Doudna lab in 2018.

---

Part of the Power List 2021

Find out more

Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products

Go to The Power List 2021